心房颤动对心尖肥厚型心肌病临床病程的影响
该研究在306例心尖肥厚型心肌病患者中评估心房颤动的发生与预后,房颤患病率25.2%、年发病率4.6%/年,独立预测因素为高龄和左房大于45 mm。随访5.5±2.0年,房颤患者全因死亡、心血管死亡和卒中发生率均高于无房颤患者,校正年龄和性别后房颤仍与全因死亡和卒中风险增加相关。
要点
- 心尖肥厚型心肌病患者房颤患病率25.2%,年发病率4.6%/年。
- 房颤独立预测因素为高龄和左房大于45 mm。
- 房颤患者全因死亡、心血管死亡和卒中发生率均高于无房颤患者。
核心结论
- 在心尖肥厚型心肌病患者中,房颤常见且与卒中和死亡风险增加相关,提示应仔细管理房颤。
研究设计与样本
- 连续纳入306例心尖肥厚型心肌病患者(68%男性,62±11岁),评估房颤发生与结局。
主要发现
- 房颤患病率25.2%,年发病率4.6%/年,独立预测因素为高龄和左房大于45 mm。
- 随访5.5±2.0年,房颤患者全因死亡11.7% vs 无房颤患者1.3%,心血管死亡6.5% vs 0.9%,卒中19.5% vs 2.6%(均p<0.05)。
- 校正年龄和性别后,房颤患者全因死亡风险HR 6.58(95%CI 1.65-26.16,p=0.007),卒中风险HR 5.13(95%CI 1.85-14.18,p=0.002)。
- 70例有抗凝指征的房颤患者中53例(76%)接受华法林。
- 15例同时有房颤和卒中的患者中8例(53%)在卒中前已检出房颤;8例卒中时使用抗凝的患者中6例发生卒中;9例房颤患者死亡中3例(33%)死因为卒中。
关键数值与推荐
- 房颤患病率25.2%,年发病率4.6%/年。
- 房颤独立预测因素为高龄和左房大于45 mm。
- 有抗凝指征的70例房颤患者中53例(76%)接受华法林。
临床怎么用
- 在心尖肥厚型心肌病患者中应仔细管理房颤。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Apical hypertrophic cardiomyopathy (ApHCM) is considered a 'benign' form of hypertrophic cardiomyopathy, with limited data on the long-term outcome. However, the clinical impact of atrial fibrillation (AF) in ApHCM is largely unknown. The hypothesis was that AF is common and has a prognostic implication in ApHCM. METHODS: The occurrence of AF and outcome was assessed in 306 consecutive patients with ApHCM (68% male, 62±11 years). RESULTS: AF occurred in 77 patients with ApHCM (prevalence, 25.2%; annual incidence, 4.6%/year) and was independently predicted by old age and large left atrium (>45 mm). Among 70 AF patients indicated with anticoagulation, 53 patients (76%) received warfarin. During a follow-up of 5.5±2.0 years, the patients with AF had a higher incidence of all-cause death, cardiovascular death and strokes (11.7% vs 1.3%, 6.5% vs 0.9% and 19.5% vs 2.6%, respectively, all p<0.05) than those without AF. When adjusted by the age and gender, those with AF still had an increased risk for all-cause death (HR 6.58; 95% CI 1.65-26.16, p=0.007) and strokes (HR 5.13; 95% CI 1.85 to 14.18, p=0.002). AF was detected before the time of stroke in 8 (53%) out of 15 patients with both AF and stroke. In addition, six out of eight patients were on anticoagulation at the time of stroke. The cause of death was a stroke in three (33%) out of nine patients with AF. CONCLUSION: In patients with ApHCM, AF was common and was associated with a substantial risk for strokes and mortality suggesting that AF should be carefully managed in ApHCM.
引用
- Lee SE, Park JK, Uhm JS, et al. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy. Heart. 2017. PMID: 28428444. doi:10.1136/heartjnl-2016-310720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。